HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 09/24/2012 -- Dehaier Medical S (NCM:DHRM) is +0.91 - +59.09% from the previous close of $1.54. It traded between $1.75 - 2.99 with total traded volume of 1129394 shares. At Current Market Price, DHRM is in distance of +40.62% from its 50-day Moving Average price of $1.7423 and +18.72% from its 200-day Moving Average price of $2.0636. Dehaier Medical Systems Ltd(NASDAQ:DHRM) shares jumped 59.09% and closed at $2.45 in the last trading session after the company announced that it has won a 3-year procurement agreement for Dehaier’s proprietary air compressors and customized trolleys from a major medical equipment manufacturer in Ukraine. During the three-year term of the agreement, the purchaser will procure Dehaier’s proprietary air compressors, customized trolleys and accessories, which will be used in hospital intensive care units, emergency rooms, operation rooms, respiratory departments and anesthesiology departments.
Can DHRM Continue To Move Higher? Find Out Here
Halozyme Therapeu (NGM:HALO) is +1.54 - +24.02% from the previous close of $6.41. It traded between $7.76 - 8.65 with total traded volume of 4892621 shares. At Current Market Price, HALO is in distance of +34.54% from its 50-day Moving Average price of $5.9091 and -6.33% from its 200-day Moving Average price of $8.4872. Halozyme Therapeutics, Inc.(NASDAQ:HALO) shares climbed 24.02% and closed at $7.95 in the previous trading session after ViroPharma and HALO announced the U.S. Food & Drug Administration has provided guidance enabling ViroPharma to resume clinical studies of the subcutaneous administration of Cinryze in combination with rHuPH20. The FDA has advised ViroPharma to amend the study protocol, allowing for increased laboratory sampling to monitor rHuPH20 antibody levels, and keep the Agency informed of elevated antibody levels during the treatment phase of the study.
Can HALO Extend Gain? Find Out Here
KB Home Common St (NYSE:KBH) is very active today and traded between $13.25 - 15.65 with total traded volume of 33219164 shares. At a current price of 15.26, KBH is +2.15 - +16.40% from the previous close of $13.11. Moreover, At Current Market Price, KBH is in distance of +34.25% from its 50-day Moving Average price of $11.3671 and +59.94% from its 200-day Moving Average price of $9.5413. KB's "surprise profit" isn't quite what it sounds like. During the quarter ending in August, the company benefitted to the tune of nearly $30 million from an insurance recovery and a tax benefit. However, the adjusted $0.12-per-share loss was still markedly better than what Wall Street was expecting. The loss was also an improvement on a $0.13 per-share loss last year, and other key metrics were moving in the company's favor -- revenue was up 16%, home deliveries rose 7%, and the average selling price of their homes climbed 8%.
Can KBH Extend Gain? Find Out Here
BioSante Pharmace (NGM:BPAX) is +0.27 - +16.07% from the previous close of $1.68. It traded between $1.71 - 1.95 with total traded volume of 2130835 shares. Keep a close eye on BPAX, as the stock has been showing unusual moves over the past weeks. At Current market price, BPAX has recovered +61.16% from its 52-week Low of 1.21 and has Pulled back -88.22% from its 52-week high of 16.56. Biosante Pharmaceuticals Inc(NASDAQ:BPAX) shares climbed 16.07% and closed at $1.95 in yesterday’s session on no official news. The company, on Sept. 4, announced that the independent Data Monitoring Committee or DMC has completed the ninth unblinded review of the LibiGel Phase III cardiovascular events and breast cancer safety study. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. LibiGel (testosterone gel) is in development for the treatment of female sexual dysfunction or FSD, specifically, hypoactive sexual desire disorder or HSDD in menopausal women.
How Should Investors React To BPAX Now? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)